Medical Tidbits, Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant

science, chemistry, technology, biology and people concept - young scientists shaking glass with reagent and making test or research in clinical laboratory

BEIJING, Jan. 4, 2016 /PRNewswire/ — Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of vaccine products, today announced positive topline results from Phase I clinical trial of PIKA rabies vaccine, an investigational vaccine designed to provide accelerated immune response against post-exposure rabies virus infection.  PIKA rabies vaccine is an innovative rabies vaccine independently developed by Yisheng Biopharma, using a novel double-strand RNA analog (“PIKA”) which acts as a toll-like receptor-3 (TLR-3) agonist to the activation of the innate immune cells. This project was named a “National Key Medicine Innovation” in 2013 and funded by the National Ministry of Science and Technology of China. read more

KineMed Enters Into Strategic Proteomic Biomarker Discovery Collaboration with Pfizer Inc.

SAN FRANCISCO–(BUSINESS WIRE)–KineMed Inc. today announced that it has entered into a strategic collaboration with Pfizer Inc. (NYSE:PFE) to discover and develop novel proprietary biomarkers in various fields of unmet medical need. KineMed’s platform technology provides a proprietary, rate-based approach for developing novel biomarkers. By utilizing mass spectroscopy and stable isotope labeling of protein turnover, KineMed biomarkers provide rates of change of key proteins involved with therapeutic efficacy and target engagement.read more

Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology

BANNOCKBURN, Ill. & COPENHAGEN, Denmark–(BUSINESS WIRE)–Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, and Symphogen, a private biopharmaceutical company developing recombinant antibodies and antibody mixtures, today announced a broad strategic immuno-oncology collaboration. read more

AntiCancer Inc. Announces Extensive Hair Growth after Transplantation of Cryopreserved Hair Follicles

SAN DIEGO–(BUSINESS WIRE)–AntiCancer Inc. has announced a new approach to hair transplantation developed using frozen cryopreserved hair follicles. Healthy mouse hair follicles were cryopreserved at -80oC. Upon thawing and transplantation to hairless “nude” mice, the transplanted follicles produced extensive hair growth similar to fresh follicles. The new study is published in PLOS ONE read more    (http://dx.plos.org/10.1371/journal.pone.0145997).

Cantargia Patent Granted by the European Patent Office

STOCKHOLM–(BUSINESS WIRE)–Cantargia AB (”Cantargia”) (STO:CANTA) has obtained a granted patent from the European Patent Office concerning IL1RAP as a target molecule for antibody based therapy and diagnostic methods of several types of solid tumors. The formal grant follows the previous ”Intention to Grant”-notification communicated October 6th, 2015.

Bactiguard Holding AB (publ): Product Approval Opens Door to China

The product approval for Bactiguard’s foley catheters for infection prevention in China, has now been announced by China Food and Drug Administration (CFDA). This opens the door to one of the largest and fastest growing markets in the world.

The product approval for Bactiguard’s foley catheters for infection prevention in China, has now been announced by China Food and Drug Administration (CFDA). This opens the door to one of the largest and fastest growing markets in the world.

VolitionRx Granted Its Third U.S. Patent

VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood tests for a broad range of cancer types and other conditions, today announced the grant of U.S. Patent Number 9222937 entitled “Method for Detecting Nucleosomes.”

The new U.S. patent, issued today and expiring in August 2032, relates to VolitionRx’s Nucleosomics® platform for the detection of fragments of chromosomes, called nucleosomes, circulating in the blood. Nucleosomes consist of a strand of DNA wrapped around eight protein molecules, called histones. They are released into the blood following the breakdown of dead cells, including cancer cells. This latest patent for the detection of nucleosomes will support the first two patents granted to VolitionRx in the U.S., which cover the Company’s core technologies: the detection of epigenetic modifications to the histones in nucleosomes that are caused by cancer; and the detection of complexes of nucleosomes that have become bound to cancer-related proteins.

Sinovac Obtains New Drug Certificate and Production License for EV71 Vaccine

BEIJING, Jan. 4, 2016 /PRNewswire/ — Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the China Food and Drug Administration (CFDA) issued the new drug certificate and production license for its Enterovirus 71 (“EV71”) vaccine. read more

 

 

Med Career News Medical Tidbits

Subscribe today for leading medical news and career advice from top medical recruiters!

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.